Discuss the role and limitations of the National Pharmaceutical Pricing Authority in ensuring both affordability and availability of essential medicines in India.

Constituted in 1997 under the Department of Pharmaceuticals, the National Pharmaceutical Pricing Authority (NPPA) fixes and monitors drug prices under the Drugs (Prices Control) Order (DPCO), 2013 [1]. Its mandate is twin — affordability and availability — and the 2026 cisplatin–carboplatin shortage shows how the two can pull apart.

Role in ensuring affordability

• Ceiling price fixation for scheduled formulations drawn from the National List of Essential Medicines; ceiling prices stood fixed for 928 scheduled formulations as of March 2025 [3].
• Measurable price relief: refixation under NLEM, 2022 cut prices by about 17% on average, saving patients an estimated ₹3,788 crore annually [2].
• Market monitoring of non-scheduled drugs, whose annual price rise is capped at 10%, with recovery of overcharged amounts [1].

Role in ensuring availability

• Paragraph 19, DPCO 2013 lets NPPA fix or revise prices in extraordinary circumstances and public interest [1].
• It has used this upward: in 2024 it revised ceiling prices of eight scheduled drugs by 50%, explicitly to meet the "twin objectives of availability and affordability" [4]; the same route was used for cisplatin and carboplatin in 2026 [6].

Limitations

• Input-cost shocks outrun fixed ceilings: platinum prices more than doubled, making these cancer drugs unviable to produce and triggering a nationwide shortage [6].
• Reactive, not anticipatory — relief came only after treatment schedules were disrupted, as a one-time hike reviewed after six months [6].
• No writ over supply chains — import dependence on platinum and West Asian shipping disruption lie outside NPPA's toolkit [6].
• Uneven outcomes: government hospitals stabilised supply while private-hospital patients still faced shortages [6]; coverage and enforcement gaps in the pricing regime persist [5].

NPPA has demonstrably lowered India's drug prices, but affordability without availability is hollow. Input-cost-indexed dynamic pricing, a shortage early-warning system, domestic API and critical-mineral resilience, and wider Janaushadhi reach can align both goals — advancing SDG-3 and the right to health under Article 21.